1.
|
9 p, 627.4 KB |
Effects of alirocumab on types of myocardial infarction : Insights from the ODYSSEY OUTCOMES trial
/
White, Harvey D. (Auckland City Hospital) ;
Gabriel Steg, P. (Royal Brompton Hospital (Londres)) ;
Szarek, Michael (SUNY Downstate Medical Center School of Public Health) ;
Bhatt, Deepak L (Harvard Medical School) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Diaz, Rafael (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Erglis, Andrejs (University of Latvia) ;
Goodman, Shaun G. (University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Department of Medicine) ;
Wouter Jukema, J. (Leiden University Medical Center) ;
Lopes, Renato D. (Duke Clinical Research Institute) ;
Mahaffey, Kenneth W. (Stanford University School of Medicine) ;
Moryusef, Angele (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals) ;
Roe, Matthew T. (Duke Clinical Research Institute) ;
Sritara, Piyamitr (Mahidol University) ;
Tricoci, Pierluigi (CSL Behring) ;
Zeiher, Andreas Michael (Goethe University) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge) ;
Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. [...]
2019 - 10.1093/eurheartj/ehz299
European heart journal, Vol. 40 Núm. 33 (january 2019) , p. 2801-2809
|
|
2.
|
10 p, 396.0 KB |
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events : The ODYSSEY OUTCOMES Trial
/
Szarek, Michael (State University of New York) ;
White, Harvey D. (University of Auckland and Green Lane Cardiovascular Services Auckland City Hospital) ;
Schwartz, Gregory G. (Division of Cardiology. University of Colorado School of Medicine) ;
Alings, Marco (Amphia Ziekenhuis Molengracht) ;
Bhatt, Deepak L (righam and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Chiang, Chern-En (Taipei Veterans General Hospital and National Yang-Ming University) ;
Diaz, Rafael (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Goodman, Shaun G. (University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, R.A. (Stanford University) ;
Jukema, J.Wouter (Leiden University Medical Center) ;
Kimura, Takeshi (Kyoto University Graduate School of Medicine) ;
Kiss, Robert Gabor (Magyar Honvédség Egészségügyi Központ) ;
Lecorps, Guillaume (Sanofi) ;
Mahaffey, Kenneth W. (Stanford University) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals Inc.) ;
Roe, Matthew T. (Duke University Medical Center) ;
Tricoci, Pierluigi (Duke University Medical Center) ;
Xavier, Denis (St. John's Medical College and Research Institute) ;
Zeiher, Andreas Michael (Goethe University) ;
Steg, Ph Gabriel (Royal Brompton Hospital (Londres)) ;
Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge) ;
Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. [...]
2019 - 10.1016/j.jacc.2018.10.039
Journal of the American College of Cardiology, Vol. 73 Núm. 4 (may 2019) , p. 387-396
|
|
3.
|
10 p, 324.1 KB |
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial
/
Jukema, J.Wouter (Leiden University Medical Center) ;
Szarek, Michael (State University of New York) ;
Zijlstra, Laurien E. (Leiden University Medical Center) ;
de Silva, H.Asita (University of Kelaniya) ;
Bhatt, Deepak L (righam and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Diaz, Rafael (Cardiovascular Institute of Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Goodman, Shaun G. (St. Michael's Hospital. University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Stanford University) ;
Karpov, Yuri (Russian Cardiological Scientific-Productive Complex) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals. Inc.) ;
Prieto, Juan C. (University of Chile Clinical Hospital) ;
Roe, Matthew T. (Duke University School of Medicine) ;
White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ;
Zeiher, Andreas Michael (Goethe University) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Steg, P.Gabriel (Royal Brompton Hospital (Londres)) ;
Cequier, Ángel (Hospital Universitari de Bellvitge) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Mata Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. [...]
2019 - 10.1016/j.jacc.2019.03.013
Journal of the American College of Cardiology, Vol. 74 Núm. 9 (march 2019) , p. 1167-1176
|
|
4.
|
12 p, 648.4 KB |
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
/
Bittner, Vera A. (University of Alabama at Birmingham) ;
Szarek, Michael (State University of New York) ;
Aylward, Philip (South Australian Health and Medical Research Institute) ;
Bhatt, Deepak L. (righam and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Díaz, Rafaël J. (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Fras, Zlatko (Univerza V Ljubljani) ;
Goodman, Shaun G. (University of Toronto) ;
Halvorsen, Sigrun (University of Oslo) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Stanford University) ;
Jukema, J. Wouter (Leiden University Medical Center) ;
Loizeau, Virginie (Sanofi) ;
Moriarty, Patrick Maurice (University of Kansas Medical Center) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals Inc.) ;
Roe, Matthew T. (Duke University School of Medicine) ;
Sinnaeve, Peter (University of Leuven) ;
Tsimikas, Sotirios (University of California San Diego) ;
Vogel, Robert A. (University of Colorado School of Medicine) ;
White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ;
Zahger, Doron (Soroka University Medical Center) ;
Zeiher, Andreas Michael (Goethe University) ;
Steg, Philippe Gabriel (Royal Brompton Hospital (Londres)) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Cequier, Ángel (Hospital Universitari de Bellvitge) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). [...]
2020 - 10.1016/j.jacc.2019.10.057
Journal of the American College of Cardiology, Vol. 75 Núm. 2 (21 2020) , p. 133-144
|
|